CStone Pharmaceuticals
HKEX:2616

Watchlist Manager
CStone Pharmaceuticals Logo
CStone Pharmaceuticals
HKEX:2616
Watchlist
Price: 1.96 HKD -1.51% Market Closed
Market Cap: 2.5B HKD
Have any thoughts about
CStone Pharmaceuticals?
Write Note

CStone Pharmaceuticals
Accrued Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

CStone Pharmaceuticals
Accrued Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accrued Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
CStone Pharmaceuticals
HKEX:2616
Accrued Liabilities
ÂĄ320.1m
CAGR 3-Years
-9%
CAGR 5-Years
36%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Accrued Liabilities
ÂĄ2.6B
CAGR 3-Years
49%
CAGR 5-Years
55%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Accrued Liabilities
ÂĄ268.5m
CAGR 3-Years
37%
CAGR 5-Years
39%
CAGR 10-Years
N/A
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
Accrued Liabilities
ÂĄ164.1m
CAGR 3-Years
50%
CAGR 5-Years
30%
CAGR 10-Years
19%
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Accrued Liabilities
ÂĄ325.2m
CAGR 3-Years
-23%
CAGR 5-Years
21%
CAGR 10-Years
45%
Imeik Technology Development Co Ltd
SZSE:300896
Accrued Liabilities
ÂĄ116.1m
CAGR 3-Years
52%
CAGR 5-Years
49%
CAGR 10-Years
N/A
No Stocks Found

CStone Pharmaceuticals
Glance View

Market Cap
2.5B HKD
Industry
Biotechnology

Cstone Pharmaceuticals Co. Ltd. engages in the research and development of highly complex biopharmaceutical products. The company is headquartered in Shanghai, Shanghai and currently employs 264 full-time employees. The company went IPO on 2019-02-26. Through its subsidiaries, the Company is primarily engaged in development, manufacturing and sales of biopharmaceutical products. Its main products include immuno-oncology drugs and molecularly targeted drugs. The firm conducts its businesses mainly in domestic market.

Intrinsic Value
3.12 HKD
Undervaluation 37%
Intrinsic Value
Price

See Also

What is CStone Pharmaceuticals's Accrued Liabilities?
Accrued Liabilities
320.1m CNY

Based on the financial report for Jun 30, 2024, CStone Pharmaceuticals's Accrued Liabilities amounts to 320.1m CNY.

What is CStone Pharmaceuticals's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 5Y
36%

Over the last year, the Accrued Liabilities growth was 20%. The average annual Accrued Liabilities growth rates for CStone Pharmaceuticals have been -9% over the past three years , 36% over the past five years .

Back to Top